The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report
- Authors: Korobko D.S.1,2, Arkhipov I.I.1, Prokaeva A.I.1, Tret'iakova E.V.1
-
Affiliations:
- State Novosibirsk Regional Clinical Hospital
- Novosibirsk State Medical University
- Issue: Vol 25, No 2 (2023): Neurology and rheumatology
- Pages: 95-100
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/131639
- DOI: https://doi.org/10.26442/20751753.2023.2.202229
- ID: 131639
Cite item
Full Text
Abstract
Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity according to magnetic resonance imaging. The drug was approved in Russia at the end of December 2020. The efficacy of siponimod was confirmed in EXPAND study, a large, randomized, double-blind phase III clinical study. This article presents three clinical cases of patients with secondary progressive multiple sclerosis from the practice of specialists of the Novosibirsk Center for Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System with an analysis of patients’ selection for siponimod treatment and an assessment of the therapy effectiveness.
Full Text
##article.viewOnOriginalSite##About the authors
Denis S. Korobko
State Novosibirsk Regional Clinical Hospital; Novosibirsk State Medical University
Author for correspondence.
Email: denis.s.korobko@gmail.com
ORCID iD: 0000-0002-7938-3782
Cand. Sci. (Med.)
Russian Federation, Novosibirsk; NovosibirskIvan Ie. Arkhipov
State Novosibirsk Regional Clinical Hospital
Email: denis.s.korobko@gmail.com
ORCID iD: 0000-0003-2740-6388
Neurologist
Russian Federation, NovosibirskAnna I. Prokaeva
State Novosibirsk Regional Clinical Hospital
Email: denis.s.korobko@gmail.com
ORCID iD: 0000-0003-2541-9302
Neurologist
Russian Federation, NovosibirskEkaterina V. Tret'iakova
State Novosibirsk Regional Clinical Hospital
Email: denis.s.korobko@gmail.com
Neurologist
Russian Federation, NovosibirskReferences
- Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet. 2017;389(10076):1357-66. doi: 10.1016/s0140-6736(16)31320-4
- Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. 2016;aww258. doi: 10.1093/brain/aww258
- Larochelle C, Uphaus T, Prat A, Zipp F. Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology? Trends Neurosci. 2016;39(5):325-39. doi: 10.1016/j.tins.2016.02.001
- Weinshenker B, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. Brain. 1989;112(1):133-46. doi: 10.1093/brain/112.1.133
- Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006;66(2):172-7. doi: 10.1212/01.wnl.0000194259.90286.fe
- Gholipour T, Healy B, Baruch N, et al. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011;76(23):1996-2001. doi: 10.1212/wnl.0b013e31821e559d
- Paz Soldán MM, Novotna M, Abou Zeid N, et al. Relapses and disability accumulation in progressive multiple sclerosis. Neurology. 2014;84(1):81-8. doi: 10.1212/wnl.0000000000001094
- Frischer J, Weigand S, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710-21. doi: 10.1002/ana.24497
- Zhao Y, Petkau A, Traboulsee A, et al. Does MRI lesion activity regress in secondary progressive multiple sclerosis? Mult Scler. 2010;16(4):434-42. doi: 10.1177/1352458509359726
- Lunde H, Assmus J, Myhr K, et al. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621-5. doi: 10.1136/jnnp-2016-315238
- Gross H, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349-57. doi: 10.2147/ndt.s132079
- Dorstyn D, Roberts R, Murphy G, Haub R. Employment and multiple sclerosis: A meta-analytic review of psychological correlates. J Health Psychol. 2017;24(1):38-51. doi: 10.1177/1359105317691587
- Macaron G, Ontaneda D. Diagnosis and Management of Progressive Multiple Sclerosis. Biomedicines. 2019;7(3):56. doi: 10.3390/biomedicines7030056
- Pan S, Gray NS, Gao W, et al. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013;4(3):333-7. doi: 10.1021/ml300396r
- Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035-47. doi: 10.1111/j.1476- 5381.2012.02061.x
- Gentile A, Musella A, Bullitta S, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016;13(1). doi: 10.1186/s12974-016-0686-4
- Kappos L, Li DKB, Stüve O, et al. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2016;73(9):1089. doi: 10.1001/jamaneurol.2016.1451
- Kappos L, Bar-Or A, Cree BAC, F et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-73. doi: 10.1016/s0140-6736(18)30475-6
- Евдошенко Е.П., Неофидов Н.А., Бахтиярова К.З., и др. Эффективность и безопасность сипонимода у пациентов с вторично-прогрессирующим рассеянным склерозом в российской популяции. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвып. 2019;119(10-2):110-9 [Ievdoshenko IeP, Neofidov NA, Bakhtiiarova KZ, et al. Effektivnost' i bezopasnost' siponimoda u patsiientov s vtorichno-progressiruiushchim rasseiannym sklerozom v rossiiskoi populiatsii. Zhurnal nevrologii i psikhiatrii im. SS Korsakova. Spetsvyp. 2019;119(10-2):110-9 (in Russian)].
- Проект клинических рекомендаций «Рассеянный склероз» (РФ) 2022–2023. Режим доступа: https://mapcms.ru/projects/recommendations/ Ссылка активна на 27.03.2023 [Draft clinical guidelines “Multiple sclerosis” (RF) 2022–2023. Available at: https://mapcms.ru/projects/recommendations/ Accessed: 27.03.2023 (in Russian)].
- Волков А.И., Попова Е.В. Новые инструменты для раннего выявления прогрессирования рассеянного склероза. Опросник MSProDiscuss. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(7 вып. 2):43-7 [Volkov AI, Popova EV. New tools for early detection of multiple sclerosis progression: MSProDiscuss questionnaire. Zhurnal nevrologii I psikhiatrii im. SS Korsakova. 2020;120(7-2):43-7 (in Russian)]. doi: 10.17116/jnevro202012007243
Supplementary files
